重大事件外國發行人報告 6-K 2026-07-21

Alterity Therapeutics 將於 BTIG 生物科技會議與投資者會面，推進 MSA 三期試驗

AI 繁中摘要

📄 **申報類型**：6-K（外國私人發行人根據《證券交易所法案》提交的報告）

🧬 **事件摘要**：  
澳洲生物科技公司 Alterity Therapeutics（ASX: ATH, NASDAQ: ATHE）宣佈，首席執行官 David Stamler 醫生將於2026年7月28日至29日參與虛擬舉行的「BTIG 生物科技會議2026」，並在會議期間與美國投資者進行一對一會面。

🔬 **業務重點**：  
- Alterity 專注於神經退化性疾病（如多系統萎縮症 MSA 及相關帕金森症候群）的疾病修飾療法。  
- 核心資產 **ATH434** 已於 MSA 患者的隨機、雙盲、安慰劑對照二期臨床試驗中展現具臨床意義的療效；開放標籤二期試驗（晚期 MSA 患者）亦錄得正面數據。  
- 公司正準備啟動 MSA 的關鍵性三期試驗（Pivotal Phase 3），MSA 屬罕見且快速進展的疾病。  
- 同時擁有廣闊的藥物發現平台，可產生專利化學化合物，針對神經疾病根本病理。

💼 **對投資者的潛在影響**：  
- 參與大型生物科技會議表明公司積極尋求美國投資者關注，有助提升市場能見度及融資機會。  
- 即將進入三期試驗是重大里程碑，成功與否將直接影響股價及公司價值；投資者需留意後續監管及臨床數據。  
- 管理層在會議中提供最新進展，或會釋出關鍵臨床時間表及戰略方向。

⚠️ **前瞻性陳述提醒**：  
本文件包含前瞻性陳述，實際結果可能因研發、融資、監管、知識產權等風險而與預期有重大差異。詳情請參閱公司向 SEC 提交的 20-F 年報及後續 6-K 報告中的「風險因素」部分。

🗓️ **資料日期**：2026年7月21日（公告授權人：CEO David Stamler）

展開英文正文

EX-99.1
2
ex_990725.htm
EXHIBIT 99.1

 ex_990725.htm
 

Exhibit 99.1

 

 

 

 

Alterity Therapeutics to Participate in the 

Virtual BTIG Biotechnology Conference 2026

 

 

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 21 July 2026:  Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer, will participate in the BTIG Biotechnology Conference 2026 taking place virtually 28-29 July 2026.

 

At the conference, Dr. Stamler will host 1-on-1 meetings with investors in the United States.  

About Alterity Therapeutics Limited 

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at https://alteritytx.com.

Authorisation & Additional information

 

This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

 

 

 

 

Contacts:

 

Investors

Elyse Shapiro

[email protected]

 

Remy Bernarda

Investor Relations Advisory Solutions

[email protected]

+1 (415) 203-6386

 

Media

Melissa Tempra

NWR Communications

[email protected]

 

Casey McDonald

Tiberend Strategic Advisors, Inc.

[email protected]

+1 (646) 577-8520

 

Forward Looking Statements

 

This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.

 

Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate.

 

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.